Gland Pharma Limited (GLAND) — Announcement | 23 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company announces investor meeting schedule
💡 Investor Takeaway
Investors can engage directly with management during scheduled meetings.

Gland Pharma announced its schedule for upcoming analyst and institutional investor meetings, listing one-on-one sessions with Nomura on August 26 and a meeting with HDFC Mutual Fund arranged by Investec on August 27. These events provide direct engagement opportunities with key investors ahead of potential market updates.

📄 View Original Announcement (PDF)

About Gland Pharma Limited (GLAND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹47,316.21 Cr P/E: 41.9 ROE: 10.9% ROCE: 15.2% Div Yield: 0.70%

View full GLAND stock details →

📡 Get AI alerts when GLAND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAND — Free

📊 More GLAND filings

See all GLAND filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAND files new disclosures

Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAND — Free

Free account · 2 AI queries/day